Advertisement
Singapore markets close in 4 hours 9 minutes
  • Straits Times Index

    3,448.43
    +4.25 (+0.12%)
     
  • Nikkei

    38,299.71
    -168.92 (-0.44%)
     
  • Hang Seng

    17,038.35
    -199.99 (-1.16%)
     
  • FTSE 100

    8,292.35
    +6.64 (+0.08%)
     
  • Bitcoin USD

    66,620.66
    -2,684.34 (-3.87%)
     
  • CMC Crypto 200

    1,361.49
    -14.23 (-1.03%)
     
  • S&P 500

    5,463.54
    +4.44 (+0.08%)
     
  • Dow

    40,539.93
    -49.41 (-0.12%)
     
  • Nasdaq

    17,370.20
    +12.32 (+0.07%)
     
  • Gold

    2,383.30
    +5.50 (+0.23%)
     
  • Crude Oil

    75.45
    -0.36 (-0.47%)
     
  • 10-Yr Bond

    4.1780
    -0.0220 (-0.52%)
     
  • FTSE Bursa Malaysia

    1,623.10
    -1.46 (-0.09%)
     
  • Jakarta Composite Index

    7,240.22
    -48.67 (-0.67%)
     
  • PSE Index

    6,583.56
    -65.67 (-0.99%)
     

Veritas, Carlyle end talks on Cotiviti stake sale - source

A general view of the lobby outside the Carlyle Group offices in Washington

(Reuters) -Veritas Capital ended talks with Carlyle Group Inc to buy a 50% stake in private healthcare technology firm Cotiviti Inc on valuation grounds, a source familiar with the matter said.

Carlyle wasn't ready to stick to the valuation that had previously been discussed in the current market conditions and submitted a revised bid in recent days, which Veritas rejected, the source said.

In February, Reuters reported that Carlyle was in talks to buy a portion of Cotiviti from Veritas Capital at a valuation of around $15 billion.

Cotiviti, which went public in 2016, was acquired by Veritas in 2018 in a take-private deal valued at $4.9 billion, as the private equity firm looked to expand its Verscend healthcare IT business.

Carlyle and Veritas declined to comment, while Cotiviti did not immediately respond to a Reuters' request for comment.

(Reporting by David Carnevali in New York and Nilutpal Timsina in Bengaluru; Editing by Subhranshu Sahu and Uttaresh Venkateshwaran)